Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation

Ma,Zhongliang; Song,Jinlian; Liu,Simin; Han,Linlin; Chen,Yangping; Wang,Yaqiu; Yu,Chundong; Hou,Lin

doi:10.3892/ol.2016.5147

Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation

Authors:
- Zhongliang Ma
- Jinlian Song
- Simin Liu
- Linlin Han
- Yangping Chen
- Yaqiu Wang
- Chundong Yu
- Lin Hou
View Affiliations

Affiliations: Department of Breast Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Laboratory Medicine, The Affiliated Qingdao Women and Children's Hospital of Qingdao, Qingdao, Shandong 266034, P.R. China, Department of PET Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Pediatrics, Jinan Children's Hospital, Jinan, Shandong 250022, P.R. China, Department of Biochemistry, Medical College, Qingdao University, Qingdao, Shandong 266021, P.R. China
Published online on: September 16, 2016 https://doi.org/10.3892/ol.2016.5147
Pages: 4021-4026

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chromodomain helicase DNA binding protein 5 (CHD5) has been identified as a tumor suppressor in mouse models. Downregulation of CHD5 gene expression is frequently observed in breast cancer cells and tissues. This may be explained by deletions or other mutations; however, alternative mechanisms require investigation. Therefore, the present study evaluated whether CHD5 aberrant methylation has a role in primary breast tumors. A total of 389 patients with primary breast cancer (including 252 paraffin‑embedded specimens and 137 fresh‑frozen samples) were enrolled in the present study. In the current study, reverse transcription‑polymerase chain reaction (RT‑PCR) and nested‑methylation‑specific PCR were used to analyze the mRNA expression and promoter methylation of CHD5 genes in a large cohort of breast cancer patients, and to investigate their associations with the clinicopathological features of tumors. CHD5 expression was significantly suppressed in breast cancer tissues compared with normal breast tissues when analyzed by RT‑PCR. Furthermore, DNA methylation of CHD5 was more prevalent in breast tumors than in normal tissues. CHD5 mRNA levels correlated with the degree of CHD5 methylation in breast cancer tissues. Clinicopathological correlation analysis revealed that CHD5 promoter methylation was associated with estrogen receptor and progesterone receptor status. Thus, downregulation of CHD5, mediated by abnormal methylation, may contribute to the development and progression of breast cancer.

View Figures

View References

1	DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics. CA Cancer J Clin. 61:409–418. 2011. View Article : Google Scholar : PubMed/NCBI
2	Fucito A, Lucchetti C, Giordano A and Romano G: Genetic and epigenetic alterations in breast cancer: What are the perspectives for clinical practice? Int J Biochem Cell Biol. 40:565–575. 2008. View Article : Google Scholar : PubMed/NCBI
3	van Wezel T, Lombaerts M, van Roon EH, Philippo K, Baelde HJ, Szuhai K, Cornelisse CJ and Cleton-Jansen AM: Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res. 7:R998–R1004. 2005. View Article : Google Scholar : PubMed/NCBI
4	Bagchi A and Mills AA: The quest for the 1p36 tumor suppressor. Cancer Res. 68:2551–2556. 2008. View Article : Google Scholar : PubMed/NCBI
5	Bièche I, Champème MH, Matifas F, Cropp CS, Callahan R and Lidereau R: Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res. 53:1990–1994. 1993.PubMed/NCBI
6	Praml C, Finke LH, Herfarth C, Schlag P, Schwab M and Amler L: Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene. 11:1357–1362. 1995.PubMed/NCBI
7	Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, et al: Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat Genet. 24:132–138. 2000. View Article : Google Scholar : PubMed/NCBI
8	Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H and Mills AA: CHD5 is a tumor suppressor at human 1p36. Cell. 128:459–475. 2007. View Article : Google Scholar : PubMed/NCBI
9	Kolla V, Zhuang T, Higashi M, Naraparaju K and Brodeur GM: Role of CHD5 in human cancers: 10 years later. Cancer Res. 74:652–658. 2014. View Article : Google Scholar : PubMed/NCBI
10	Mulero-Navarro S and Esteller M: Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics. 3:210–215. 2008. View Article : Google Scholar : PubMed/NCBI
11	Clark SJ and Melki J: DNA methylation and gene silencing in cancer: Which is the guilty party? Oncogene. 21:5380–5387. 2002. View Article : Google Scholar : PubMed/NCBI
12	Das PM and Singal R: DNA methylation and cancer. J Clin Oncol. 22:4632–4642. 2004. View Article : Google Scholar : PubMed/NCBI
13	Jones PA and Baylin SB: The epigenomics of cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
14	Holliday R: The inheritance of epigenetic defects. Science. 238:163–170. 1987. View Article : Google Scholar : PubMed/NCBI
15	Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M, Green R, Lee E, Smoot DT and Ashktorab H: Distinct high-profile methylated genes in colorectal cancer. PLoS One. 4:e70122009. View Article : Google Scholar : PubMed/NCBI
16	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
17	Veronesi U, Viale G, Rotmensz N and Goldhirsch A: Rethinking TNM: Breast cancer TNM classification for treatment decision-making and research. Breast. 15:3–8. 2006. View Article : Google Scholar : PubMed/NCBI
18	Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP, Lin MC, Wang J, He H, Jiang SH, et al: Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology. 131:1835–1843. 2006. View Article : Google Scholar : PubMed/NCBI
19	Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, et al: CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst. 100:940–949. 2008. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Lau KK, So LK and Lam YW: CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J Biomed Sci. 16:952009. View Article : Google Scholar : PubMed/NCBI
21	Fatemi M, Paul TA, Brodeur GM, Shokrani B, Brim H and Ashktorab H: Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. Cancer. 120:172–180. 2014. View Article : Google Scholar : PubMed/NCBI
22	Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL and Campbell IG: Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia. 10:1253–1258. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zhao R, Yan Q, Lv J, Huang H, Zheng W, Zhang B and Ma W: CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer. 76:324–331. 2012. View Article : Google Scholar : PubMed/NCBI
24	Koyama H, Zhuang T, Light JE, Kolla V, Higashi M, McGrady PW, London WB and Brodeur GM: Mechanisms of CHD5 Inactivation in neuroblastomas. Clin Cancer Res. 18:1588–1597. 2012. View Article : Google Scholar : PubMed/NCBI
25	Rinner B, Gallè B, Trajanoski S, Fischer C, Hatz M, Maierhofer T, Michelitsch G, Moinfar F, Stelzer I, Pfragner R and Guelly C: Molecular evidence for the bi-clonal origin of neuroendocrine tumor derived metastases. BMC Genomics. 13:5942012. View Article : Google Scholar : PubMed/NCBI
26	Futscher BW: Epigenetic changes during cell transformation. Adv Exp Med Biol. 754:179–194. 2013. View Article : Google Scholar : PubMed/NCBI
27	Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T and Orucevic A: Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J. 19:22–30. 2013. View Article : Google Scholar : PubMed/NCBI
28	Bardou VJ, Arpino G, Elledge RM, Osborne CK and Clark GM: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 21:1973–1979. 2003. View Article : Google Scholar : PubMed/NCBI
29	Yan L, Yang X and Davidson NE: Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia. 6:183–192. 2001. View Article : Google Scholar : PubMed/NCBI
30	Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG and Davidson NE: Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60:6890–6894. 2000.PubMed/NCBI
31	Wu X, Zhu Z, Li W, Fu X, Su D, Fu L, Zhang Z, Luo A, Sun X, Fu L and Dong JT: Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res. 14:R732012. View Article : Google Scholar : PubMed/NCBI